Neurocrine Biosciences (NBIX) Gross Profit (2017 - 2026)
Neurocrine Biosciences' Gross Profit came in at $1.1 billion for Q3 2026, up 40.2% from $781.9 million a year earlier and up 17.1% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Gross Profit (2017 - 2026) Analysis & Trends
Over the trailing twelve months to Sep 30, 2026, Neurocrine Biosciences reported Gross Profit of $3.62 billion, up 37.0% year-over-year; for FY2025, it was $2.81 billion, up 21.0% from FY2024.
- Gross Profit has increased in each of the last nine years, with a five-year compound annual growth rate of 22.1% (FY2020 to FY2025).
- Going back by year, Gross Profit was $2.32 billion in FY2024 (+25.7%), $1.85 billion in FY2023 (+26.1%), $1.47 billion in FY2022 (+30.9%) and $1.12 billion in FY2021 (+8.1%).
- The Q3 2026 figure represents the highest quarterly Gross Profit in data going back to Q2 2017.
- Year-over-year, Gross Profit has increased for 21 consecutive quarters, with growth averaging 28.0% over the last eight quarters.
- Across the past five years, year-over-year growth in Gross Profit ran from 10.9% in Q1 2025 to 42.1% in Q1 2026.
- Business Quant data shows NBIX's Gross Profit at $935.8 million (Q2 2026), $800.7 million (Q1 2026) and $784.9 million (Q4 2025) in the three quarters before Q3 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 1.10 Bn |
| Jun 30, 2026 | 935.80 Mn |
| Mar 31, 2026 | 800.70 Mn |
| Dec 31, 2025 | 784.90 Mn |
| Sep 30, 2025 | 781.90 Mn |
| Jun 30, 2025 | 677.20 Mn |
| Mar 31, 2025 | 563.40 Mn |
| Dec 31, 2024 | 618.40 Mn |
| Sep 30, 2024 | 614.10 Mn |
| Jun 30, 2024 | 581.00 Mn |
| Mar 31, 2024 | 507.80 Mn |
| Dec 31, 2023 | 506.70 Mn |
| Sep 30, 2023 | 487.60 Mn |
| Jun 30, 2023 | 441.20 Mn |
| Mar 31, 2023 | 411.90 Mn |
| Dec 31, 2022 | 404.30 Mn |
| Sep 30, 2022 | 381.80 Mn |
| Jun 30, 2022 | 373.40 Mn |
| Mar 31, 2022 | 306.00 Mn |
| Dec 31, 2021 | 307.90 Mn |
API Access
Neurocrine Biosciences Gross Profit API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gross-profit&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gross-profit", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gross-profit&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();